NDAINTRAVENOUSPOWDER
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
LOCAMETZ (kit for the preparation of gallium ga 68 gozetotide) by Novartis is 68 gozetotide binds to psma. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCAMETZ is a kit for preparing Gallium GA-68 gozetotide, a PET imaging agent that binds to PSMA (prostate-specific membrane antigen) on malignant prostate cancer cells. The agent uses gallium-68, a positron-emitting radionuclide, to enable PET imaging of PSMA-expressing tumors. It is administered intravenously as a powder formulation requiring preparation prior to use.
Peak9.8 years to LOE
Product is in peak lifecycle stage with minimal current competitive pressure, suggesting stable near-term positioning but potential team volatility as LOE approaches in ~10 years.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows PET.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOCAMETZ offers stability within a peak-lifecycle, minimally competitive product with strong patent protection through 2028–2036. However, the product shows limited linked job openings and no active clinical development, suggesting a mature, smaller brand team focused on execution rather than expansion.
Brand ManagerMedical Science Liaison (MSL)
Worked on LOCAMETZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.